Introduction
The World Health Organization calculates that over -six hundred and fifty million people worldwide suffer of some form of liver disease, including thirty million Americans. On a worldwide base, approximately one to two million deaths are accounted to liver related diseases annually. Around the globe, China has the world's largest population of Hepatitis B patients (approx. 120 million) with five hundred thousand people dying of liver illnesses every year (CDC, 2007; WHO, 2008) . In the US alone, five hundred thousand critical liver problem episodes are reported every year requiring hospitalization with great burden to the patients and a huge cost to the health care system. In the European Union and United States of America alone, over eighty one thousand and twenty six thousand people died of chronic liver disease in 2006 , respectively (CDC, 2007 Eurostat, 2007) . In these patients, liver transplantation is presently the only proven therapy able to extend survival for end-stage liver disease. It is also the only treatment for severe acute liver failure and to some forms of inborn errors of metabolism.
The road to successful liver grafting in humans has been long and fraught with many obstacles. Experimental attempts at liver transplantation originally took place in the 1950s and 1960s, but human liver transplantation did not become a reality until 1963 (Starzl & Demetris, 1990) . Although unsuccessful, Dr. Starzl's attempt at liver transplantation was a milestone in surgery. However, it took nearly 20 years to develop a surgical procedure for orthotopic liver transplantation (OLT) that was safe to apply in humans. In 1983, the National Institutes of Health (NIH) held the Consensus Development Conference on Liver Transplantation. The most important outcome of this conference was OLT became an accepted therapeutic modality for some patients with end-stage liver disease (NIH, 1983) . The ideal liver transplant candidate needed to comply with ten conditions ( Table 1) as well as ten absolute contraindications and five relative contraindications ( Table 2) . Taking into account the multitude of criteria for OLT, few patients were deemed eligible. Furthermore, the University of Pittsburgh was the only liver transplant center in the United States in 1983. Currently, 120 liver transplant centers in the United States are registered with the United Network for Organ Sharing (UNOS), the organization that manages the nation's organ transplant system, and 145 transplant centers from 24 European countries are participating in the European Liver Transplant Registry (ELTR). As reported in the UNOS database, 111,824 liver transplantations have been performed in the United States through December 2010 (UNOS, 2010) . Likewise, 100,542 liver transplantations have been performed in Europe with an average of 5,562 transplantations per year in the past decade (ELTR, 2010 Since the first OLT was performed, the field has changed dramatically. Improvements in surgery, anaesthesia, immunosuppression, and control of infection have translated into increased access and better patient outcomes. In the pioneering days of OLT, triple-drug therapy (corticosteroids, azathioprine [AZA] , and antilymphocyte globulin [ALG]) was used to prevent and treat rejection. The development of a powerful immunosuppressive agent, cyclosporine (CsA), in the late 1970s was one of the most significant events in modern transplantation. By 1984, all transplant centers in the United States used double therapy of corticosteroids and CsA as the maintenance immunosuppressive regimen. During the 1990s, tacrolimus (TAC) emerged as the mainstay maintenance immunosuppressive agent in OLT, with or without corticosteroids. More recently, mycophenolate mofetil (MMF) has replaced the use of AZA in many centers. Before the advent of CsA, 5-year survival after OLT was less than 20%. Current survival rates 1, 3, and 5 years after liver transplantation in the United States are 88%, 80%, and 75%, respectively (UNOS, 2010) .
Advancements in surgical techniques and technologies also account for the increased success of OLT. In particular, the standardization of biliary tract reconstruction, advances in retransplantation, and improvements in surgical technology help explain better patient outcomes. Examples of developments in technology include pump-driven veno-venous bypass that does not require recipient heparinization, rapid infusion, and autologous autotransfusion devices. Additionally, improved procurement and preservation techniques for the donor liver and increased insight into the management of potentially fatal complications have led to improved patient morbidity and mortality.
Evolution of liver transplant indications
Nowadays, liver transplantation is indicated for acute or chronic liver failure of any cause ( Table 3) .
Cirrhosis due to chronic hepatitis C infection is one of the most common indications for liver transplantation in the United States and Europe. Despite effective antiviral treatments including Pegylated Interferon, Ribavirin, and direct-acting antiviral agents (DAAs), this indication is likely to remain important for the coming decades given the large prevalence of chronic hepatitis C infection and the propensity of the disease to lead to cirrhosis and hepatocellular carcinoma (HCC) (Merion, 2010) .
Chronic hepatitis B has become a less common indication, mostly due to the advent of universal vaccination. Additionally, dramatic improvements in the treatment of hepatitis B, such as the development of nucleoside/nucleotide analogues, has reduced the number of patients with chronic hepatitis B progressing to end-stage liver disease. However, in parts of the world where chronic hepatitis B is endemic, including much of Asia, this remains the most common indication (Perrillo, 2009 ).
Alcohol-related liver disease is an important indication for OLT in Western countries and is oftentimes associated with concomitant hepatitis C infection. In the past, patients with alcohol-related liver disease and alcohol dependence were often refused access to liver transplantation due to unjust societal allocation of scarce donor organs. However, a careful assessment with the support of a health care professional experienced in the management of patients with addictive behavior is associated with low rates of recidivism after OLT (Lucey, 1992) . Nowadays, this indication has become more commonly accepted, as long as patients demonstrate sobriety of at least 6 months duration. Nonalcoholic fatty liver disease (NAFLD) is becoming one of the most common liver disorders in developed countries. Because this disorder can lead to cirrhosis in a number of patients and is associated with an increased risk of hepatocellular carcinoma (HCC), it is an increasingly frequent indication for liver transplantation (Burke, 2004) . Considering the current obesity epidemic, NAFLD may become the most common indication for liver transplantation in the coming years.
Year of Transplant
Primary HCC is a unique and evolving indication for liver transplant. Initially, outcomes in liver transplantations for patients with unresectable HCC were not encouraging. Ninety percent of those transplanted for HCC developed recurrent disease within 2 years. As a result, HCC was considered a contraindication to transplantation for a number of years.
Ongoing research on HCC post-transplant elucidated that important predictors of recurrence are tumor characteristics, such as tumor size, stage, and grade, number of nodules, micro-or macrovascular invasion, serum levels of alpha-fetoprotein, and demonstrated absence of extrahepatic spread. In 1996, Mazzaferro and colleagues defined the Milan criteria, which require a single tumor ≤ 5 cm in diameter or no more than three tumor nodules, each ≤ 3 cm in diameter. Liver transplant in patients meeting the Milan criteria have excellent outcomes and low recurrence rates (Mazzaferro, 1996) .
Augmentations to the Milan criteria are currently being debated in the liver transplant community. The San Francisco criteria, which require either a single lesion ≤ 6.5 cm or up to three lesions none of which is >4.5 cm and with total tumor diameter ≤ 8 cm, have been widely debated, but no consensus has yet emerged (Yao, 2001) . Finally, more attention has been given to the role of downstaging by locoregional therapy for otherwise unsuitable candidates. Treatments to shrink nodules, including radiofrequency ablation, transcatheter arterial chemoembolization, and novel thermal and non-thermal techniques for tumor ablation offer strategies for subsequent transplantation in patients with more advanced lesions.
Many inborn errors of metabolism have been successfully treated with liver transplantation (Kayler, 2003) .
Acute liver failure has long been considered an appropriate indication for liver transplant.
Patients with fulminant hepatic failure should be referred to a transplant center as quickly as possible for critical care management. If given appropriate critical care support, many patients spontaneously recover. Patients predicted to have little chance of spontaneous recovery should undergo transplantation as soon as possible. New technologies using bioartificial liver devices including both a biological component and an artificial scaffold may offer some promises for patients with acute liver failure. However, these technologies have not become widely available yet, and therefore OLT remains an important treatment (Demetriou, 2004; Ellis, 1996) .
Historical contraindications to OLT

Absolute contraindications
Splanchnic venous thrombosis
Splanchnic venous thrombosis and portal hypertension surgery are both part of the natural evolution of cirrhosis. Intra-operative mortality during OLT with these conditions was once nearly 50%. Those that survived OLT oftentimes had morbid conditions that diminished the utility of the transplant. In recent times, several technical advances have been made to overcome this problem. Eversion thrombectomy is a good treatment option for a majority of patients with splanchnic venous thrombosis. If eversion thrombectomy is not possible, a free iliac interposition graft between the allograft portal vein and the superior mesenteric vein is indicated. Sometimes it is possible to connect the allograft portal vein to a collateral vein. In cases of extended splanchnic thrombosis, cavo-portal hemi-transposition or combined liverintestinal transplantation are the last resorts for treatment (Lerut, 1997) .
Hepatopulmonary Syndrome (HPS)
HPS is defined as a pO2 < 70 mmHg in an upright position. It is present in up to 20% of cirrhotic patients. Even in cases where oxygen saturation is below 50 mmHg, this situation can be reversed by a successful OLT. The post-transplant recovery is usually more complicated necessitating adapted respiratory care. The pre-transplant baseline macroaggregated albumin shunt fraction may indicate the limits of correction following OLT (Starzl, 1990) .
Sepsis outside the hepatobiliary system
Active extra-hepatic infection compromises outcomes of OLT. Nonetheless, transplantation can be performed successfully if the infection is confined to the lungs or the ascites and does not cause hemodynamic instability (Starzl, 1990) . Post-transplant care is usually much more prolonged and expensive if the patient has sepsis outside the hepatobiliary system.
Primary malignant disease outside the hepatobiliary system
Based on the embryological development theory, Starzl advocated the 'en block' or 'cluster transplant' in order to treat extended hepatobiliary malignancies and liver metastases from neuroendocrine tumors. Although initial success was promising, longterm results were disappointing. (Lerut, 2007 Starzl, 1990) .
Pre-OLT malignancies or malignancies discovered incidentally during the OLT-procedure are no longer contraindications to OLT as shown by the Kings' College study. Metastatic hepatobiliary malignancy is an emerging indication for OLT. After successful chemotherapeutic treatment of hepatic and thoracic tumor involvement in children with hepatoblastoma, excellent results have been obtained with OLT. Similarly, excellent longterm results have been obtained for epithelioid hemangio-endothelioma. In the latter group some centers propose sequential or simultaneous hepatopulmonary transplantation (Lerut, 2007) .
The role of OLT in the treatment of neuroendocrine tumors with hepatic involvement is continuously evolving. Excellent OLT results can be obtained in select, young (<50 years) patients after R0 resection of the primary tumor for more than six months prior to transplant. Furthermore, if the primary lesion has favorable tumor biology (as expressed by a Ki67 index of < 5-10%) and has a portal vein drainage, results are significantly improved (Bonaccorsi-Riani, 2010) .
It is evident that all oncologic patients that undergo OLT will benefit from adapted immunosuppression. Minimization of immunosuppression and use of the m-TOR inhibitor, rapamycin, are of paramount importance. Rapamycin has antitumor activity based on antiangiogenic properties.
The most recent development in the field of OLT is the treatment of metastatic colorectal malignancy. The Oslo-SECA (SEcondary CAncer) study indicates that OLT will have a role in the treatment of colorectal metastases on the condition that adapted chemotherapy and immunosuppression are employed after the transplant procedure. Preliminary results obtained in the Oslo-SECA cases show nearly 50% 5-year survival after OLT (Foss, 2011) .
Alcohol abuse
OLT in active alcoholic patients has always been discussed heavily within the medical community (Starzl, 1990) . The 'six month abstinence rule' is not generally enforced, and some French groups even advocate OLT in cases of severe acute alcoholic hepatitis (Mathuri, 2005) .
Drug abuse
Although also heavily debated, some groups in New York showed that OLT can be successful in recipients on methadone maintenance.
Both alcohol and drug abusers need exceptionally tight follow-up during the pre-and posttransplant period. It is of utmost importance to take familial, professional, and social conditions into consideration in these potential patients (Starzl, 1990) .
Advanced cardiopulmonary disease
Two-staged cardiac and hepatic transplantion is becoming more frequent (Starzl, 1990) . Several case reports have been published about simultaneous liver and heart transplantation in the context of familial amyloid polyneuropathy (FAP) and hemochromatosis. Simultaneous OLT with coronary, valvular, or arrythmia surgery has also been reported. These surgeries are complex and have stimulated major interest in both cardiovascular and hepatic experts of transplant centers.
Viral infections
Viral cirrhosis was once an absolute contraindication to OLT because of the universal recurrence of the disease in the liver allograft (Lerut, 1998) . The landmark paper of Samuel in 1993 showed that adequate antiviral prophylaxis using specific anti-HBs antibodies protects the allograft from reinfection (Samuel, 1993) . Further improvement has been achieved by combining nucleoside and nucleotide analogues with immunoglobulins. This prophylactic combination was able to reduce the incidence of allograft reinfection from 100% to 5%. Moreover, those with HBV gain an immunologic advantage from immunoglobulin treatment due to immunoglobulins producing a tolerogenic effect on dendritic cells.
Age
Increasing numbers of transplants are done in patients aged over 65 and 70 years of age (Starzl, 1990) . The initial Pittsburgh results have now been confirmed by most transplant centers.
Inability to accept or understand the procedure
OLT is accessible to patients in all levels of society. Successful OLT has been reported in D o w n S y n d r o m e p a t i e n t s a n d i n d r u g a b u s ers. Adequate preparation by medical, paramedical, and clinical coordinator teams is of utmost importance in complicated clinical scenarios.
Relative contraindications
Intra-hepatic or biliary sepsis
Chronic biliary infection is frequent in Caroli disease, primary sclerosing cholangitis, and secondary sclerosing cholangitis. Because the infection is usually confined to the liver, outcome of OLT is excellent as transplantation removes the source of the infection. OLT is especially valuable in these patients as it dramatically improves their quality of life.
Advanced liver disease in abstinent alcoholic patients
The Model for End-Stage Liver Disease (MELD) scoring system aims to reduce liver waitlist mortality by transplanting sicker patients more rapidly. Abstinent alcoholics frequently belong to the sickest patient groups. Nowadays, OLT is a very good indication in such patients if the recipient remains abstinent and is compliant. If the recipient remains abstinent, alcoholic cirrhosis is one of the best indications for OLT as this is the only disease that does not recur in the allograft. Moreover, abstinent alcoholics that receive OLT offer a unique opportunity to study the effect of immunosuppression withdrawal without primary disease involvement in the allograft.
Previous abdominal surgery
Many transplant recipients have undergone previous abdominal and right upper quadrant surgery. These interventions can compromise the transplant procedure. Thus, exploratory or staging laparotomies as well as unnecessary cholecystectomies and cyst fenestrations should be avoided in future OLT patients. Interventional radiology procedures such as the Transjugular Intrahepatic Portosystemic Shunt (TIPSS) are preferred in potential OLT recipients instead of portal hypertension surgery. In cases where portal hypertension surgery cannot be avoided, meso-caval or spleno-renal shunts are the preferred options leaving the hilar region intact.
HIV infection
HIV patients that are well controlled on Highly Active Antiretroviral Therapy (HAART) are generally not contraindicated for OLT. The indication for OLT relates more so to concomitant HCV and/or HBV infection. Co-infected patients are at higher post-OLT infectious risk. Particular attention should be given to the interaction between anti-viral drugs and calcineurin inhibitors.
Positive HBsAg status
See above.
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Future perspectives
Criteria for placement on the waiting list have become more quantitative. Continuous refinement of the allocation system will improve the management of the waiting list (Metsellaar, 2011) .
Alternative techniques such as split liver transplantation (SLT) and living donor liver transplantation (LDLT) will allow for expansion of the allograft pools. The bipartition of the liver is especially important in pediatric patients for whom size-matched whole liver allografts are scarce. Split grafts have been associated with reduction in the risk of death on the pediatric waiting list. However, SLT is much less successful in the adult-adult SLT. Donor selection for splitting and technical and logistical expertise to decrease total ischemia time are important factors in successful transplantation. A better understanding of the liver anatomy and improving surgical skills have allowed living liver donation to become a routine procedure in some centers. Given the major risks of the operation required for the donor, whether this procedure will ever find wide application is unclear.
As there will always be more potential recipients than donors, many researchers are working in the field of artificial tissue engineering and regenerative medicine (RM) (Orlando, 2011a (Orlando, , 2011b (Orlando, , 2011c (Orlando, , 2011d (Orlando, , 2012a (Orlando, , 2012b (Orlando, , 2012c . RM holds the promise of regenerating tissues and organs by either stimulating previously irreparable tissues to heal themselves, by treating liver disease with cell therapies, or by manufacturing tissues ex vivo using extracellular matrix (ECM) scaffolds.
This last approach, uses ECM scaffolds that have an intact but decellularized vascular network that is repopulated with autologous or allogeneic stem cells and/or adult cells. Liver ECM scaffolds may be produced from humans or animals. In the latter case, human cells are used to repopulate a scaffold of animal origin, coining a new concept called semi-xenotransplantation (Orlando, 2011a (Orlando, , 2011b . Importantly, preemptive transplantation with regenerated tissues will improve outcomes, especially in cases of metabolic and cystic liver disease.
Future progress in the medical treatment of oncology will enhance outcomes in OLT (Lerut, 2007 Bonaccorsi-Riani, 2010 , Foss, 2011 . As treatments of vascular tumors, advanced hepatocellular cancer, cholangiocellular cancer, neuroendocrine tumors, and colorectal liver metastases improve, indications for OLT in the 21 st century will become more inclusive of advanced oncologic disease states.
Combined organ transplantation is becoming more frequent as many liver diseases are accompanied by renal function impairment. Nowadays, 15% of all liver recipients have combined liver-kidney transplantation.
Transplant teams should focus more on late morbidity and mortality. Currently, the majority of long-term survivors die from infectious disease, cardiovascular disease, or cancer while having a functional graft. This mortality is directly related to the strength of the maintenance immunosuppression. Minimization or even withdrawal of immunosuppressive protocols must become a priority in organ transplantation (Lerut, 2003 (Lerut, , 2008 . Unfortunately, tolerance protocols are frequently based on a trial and error approach, as good markers to predict tolerance are not yet available (Lerut, 2006) . As the liver is an immunoprivileged organ with relatively high resistance against immune responses, liver recipients should be at the forefront of this research.
Conclusion
Since the first transplantation was performed much progress has been made in the field of OLT. Indications for liver transplant have evolved to include previously contraindicated conditions such as those with hepatocellular carcinoma and alcohol-related liver disease. All but one (active sepsis outside the biliary system) contraindication to OLT has been eliminated. As a result, more than 200,000 patients have been transplanted, many with excellent long-term success. With indications to transplantation increasing and contraindications waning, many more patients will be transplanted in the future.
The future of liver transplantation will be no less challenging for its practitioners. The main challenge is the shortage of organs, and many strategies are in place to address this problem.
In the near future, immunologic discoveries will allow for an immunosuppression-free state of many recipients. This will guarantee better quality of life and similar survival expectancy as non-transplanted patients. Regenerative medicine technology applied to liver transplantation has the potential to meet the two major needs: namely, the identification of a potentially inexhaustible source of livers and an immunosuppression-free state. In the ideal scenario, livers will be manufactured from autologous cells with no need for anti-rejection therapy.
